clinical trial · NCT05526755
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
AstraZeneca·phase2·active not recruiting·n = 188
Stage II-IIIB Non-small Cell Lung CarcinomaOsimertinib 80 mg/40 mg
brief summary
To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.
started
Mar 6, 2023
primary completion
Nov 22, 2029
completion
Nov 22, 2029
last updated
Mar 4, 2026
detailed description
This is a phase 2 open-label study to assess the efficacy and safety of osimertinib in participants with stage II-IIIB NSCLC with sensitising EGFR mutations. The study is designed to evaluate 5 years of adjuvant osimertinib therapy.
official title
An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants With EGFRm-positive Stage II-IIIB NSCLC, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol